抗白细胞介素-17单克隆抗体司库奇尤单抗治疗银屑病 - Suppr

Suppr

超能文献

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

作者信息

Reich Kristian

出版信息

N Engl J Med. 2012 Jul 19;367(3):274; author reply 275. doi: 10.1056/NEJMc1205835.

DOI:10.1056/NEJMc1205835

PMID:22808966

Abstract

摘要

相似文献

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274; author reply 275. doi: 10.1056/NEJMc1205835.

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274-5; author reply 275. doi: 10.1056/NEJMc1205835.

To be 17 again--anti-interleukin-17 treatment for psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1251-2. doi: 10.1056/NEJMe1201071.

IL-17 antibodies gain momentum.

Nat Rev Drug Discov. 2013 Nov;12(11):815-6. doi: 10.1038/nrd4152.

Anti-IL17 therapies for psoriasis.

Expert Opin Biol Ther. 2019 Jan;19(1):45-54. doi: 10.1080/14712598.2019.1555235. Epub 2018 Dec 8.

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.

Ixekizumab for treatment of psoriasis.

Expert Rev Clin Immunol. 2015 Apr;11(4):435-42. doi: 10.1586/1744666X.2015.1023295. Epub 2015 Mar 8.

The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.

J Cutan Med Surg. 2016 Nov;20(6):509-516. doi: 10.1177/1203475416651605. Epub 2016 May 20.

The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.

Drugs Today (Barc). 2019 Sep;55(9):587-593. doi: 10.1358/dot.2019.55.9.3020159.

Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.

Actas Dermosifiliogr. 2017 May;108(4):305-314. doi: 10.1016/j.ad.2016.09.021. Epub 2016 Nov 22.

引用本文的文献

Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.

J Inflamm Res. 2025 Feb 10;18:2045-2072. doi: 10.2147/JIR.S506103. eCollection 2025.

Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.

Int J Mol Sci. 2021 May 7;22(9):4983. doi: 10.3390/ijms22094983.

Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis.

Sci Rep. 2017 Sep 11;7(1):11198. doi: 10.1038/s41598-017-10580-y.

IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα.

Exp Ther Med. 2016 Feb;11(2):631-636. doi: 10.3892/etm.2015.2939. Epub 2015 Dec 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274; author reply 275. doi: 10.1056/NEJMc1205835.

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

N Engl J Med. 2012 Jul 19;367(3):274-5; author reply 275. doi: 10.1056/NEJMc1205835.

To be 17 again--anti-interleukin-17 treatment for psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1251-2. doi: 10.1056/NEJMe1201071.

IL-17 antibodies gain momentum.

Nat Rev Drug Discov. 2013 Nov;12(11):815-6. doi: 10.1038/nrd4152.

Anti-IL17 therapies for psoriasis.

Expert Opin Biol Ther. 2019 Jan;19(1):45-54. doi: 10.1080/14712598.2019.1555235. Epub 2018 Dec 8.

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.

Ixekizumab for treatment of psoriasis.

Expert Rev Clin Immunol. 2015 Apr;11(4):435-42. doi: 10.1586/1744666X.2015.1023295. Epub 2015 Mar 8.

The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.

J Cutan Med Surg. 2016 Nov;20(6):509-516. doi: 10.1177/1203475416651605. Epub 2016 May 20.

The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.

Drugs Today (Barc). 2019 Sep;55(9):587-593. doi: 10.1358/dot.2019.55.9.3020159.

Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.

Actas Dermosifiliogr. 2017 May;108(4):305-314. doi: 10.1016/j.ad.2016.09.021. Epub 2016 Nov 22.

引用本文的文献

Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.

J Inflamm Res. 2025 Feb 10;18:2045-2072. doi: 10.2147/JIR.S506103. eCollection 2025.

Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.

Int J Mol Sci. 2021 May 7;22(9):4983. doi: 10.3390/ijms22094983.

Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis.

Sci Rep. 2017 Sep 11;7(1):11198. doi: 10.1038/s41598-017-10580-y.

IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα.

Exp Ther Med. 2016 Feb;11(2):631-636. doi: 10.3892/etm.2015.2939. Epub 2015 Dec 16.